What is Ocular Therapeutix's G&A?

Ocular Therapeutix (OCUL) reported G&A of $20.01M in Q1 2026.

How has Ocular Therapeutix's G&A changed year-over-year?

Ocular Therapeutix's G&A increased by 22.4% year-over-year, from $16.35M to $20.01M.

What is the long-term trend for Ocular Therapeutix's G&A?

Over 4 years (2021 to 2025), Ocular Therapeutix's G&A has grown at a 19.2% compound annual growth rate (CAGR), from $31.88M to $64.38M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ocular Therapeutix OCUL G&A

G&A at other companies

Kodiak Sciences IncKOD

$11.23M-27.2%

PBH

Prestige Consumer HealthcarePBH

$30.28M+11.9%

Xenon PharmaceuticalsXENE

$23.82M+25.1%

Erasca, Inc.ERAS

$10.65M+10.2%

PVL

Palvella TherapeuticsPVLA

$5.52M+45.4%

Other financials

Income statement

See full

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

See full

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

See full

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

See full

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

See full

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

See full

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's G&A?: Ocular Therapeutix (OCUL) reported G&A of $20.01M in Q1 2026.
How has Ocular Therapeutix's G&A changed year-over-year?: Ocular Therapeutix's G&A increased by 22.4% year-over-year, from $16.35M to $20.01M.
What is the long-term trend for Ocular Therapeutix's G&A?: Over 4 years (2021 to 2025), Ocular Therapeutix's G&A has grown at a 19.2% compound annual growth rate (CAGR), from $31.88M to $64.38M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.